Introduction
============

Allogeneic stem cell transplantation (allo-SCT) is an established method in the treatment of high-risk acute leukemia in children (Bader et al., [@B3]; Rettinger et al., [@B42]), and may also play a role in the treatment of high-risk soft tissue sarcoma in children. Especially patients with primary alveolar rhabdomyosarcoma (RMS) above the age of 10 years with bone or bone marrow (BM) metastases have no realistic chance to survive their disease with conventional treatment (Koscielniak et al., [@B25]; Klingebiel et al., [@B23]; Perez et al., [@B34]). By evaluating the impact of allo-SCT in both, leukemia and soft tissue sarcoma patients, minimal residual disease (MRD) after transplantation is the reason for disease recurrence, and therefore is the strongest negative effector of the therapeutic success of allo-SCT. Once a stem cell recipient relapses, further therapeutic options are limited. For instance, donor lymphocyte infusion (DLI) is only efficacious for a limited number of diseases, and the high T cell doses required for DLI raise the risk for severe graft-versus-host-disease (GvHD; Rettinger et al., [@B42]).

Cytokine-induced killer (CIK) cells are known in principle to be capable of eradicating a variety of both hematological and solid malignancies in a non-MHC-restricted manner, without possessing significant alloreactive potential (Takayama et al., [@B54]; Baker et al., [@B4]; Edinger et al., [@B8]; Kornacker et al., [@B24]; Sangiolo et al., [@B44]; Kim et al., [@B20],[@B21],[@B22]). In recent years, the application of CIK cells has evolved from experimental observations into early clinical studies (Introna et al., [@B15]), and CIK cells are now considered superior to lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL) for cancer immunotherapy. In this context, CIK cells exhibit a stronger anti-tumor effect and continue to differentiate and survive *in vivo* without maintenance of exogenous cytokines after injection (Olioso et al., [@B33]). Activated CIK cells represent a heterogeneous population of polyclonal T cells sharing both natural killer (NK) phenotype and functional properties of NK cells (Pievani et al., [@B37]). CIK cells can be efficiently expanded *in vitro* from peripheral blood (PB), BM mononuclear cells and umbilical cord blood by addition of interferon (IFN)γ, activating antibody directed against CD3 and interleukin (IL)-2 (Lu and Negrin, [@B29]; Thorne et al., [@B55]). We recently used IL-15 for further CIK cell activation and expansion (Rettinger et al., [@B41]). We could show that IL-15-activated CIK cells have an increased anti-leukemic potential *in vitro* compared to conventional IL-2-activated CIK cells. Furthermore, our modified protocol allowed us to shorten *ex vivo* expansion time of CIK cells. Therefore, in this study we used IL-15-activated CIK cells after 10 days of culture for *in vitro* and *in vivo* analyses.

NOD/SCID/IL-2Rγc^−^ (NSG) mice have a phenotype of severe combined immunodeficiency lacking functional T, B, and NK lymphocytes and, therefore, permit establishment of human xenografts (Ishikawa et al., [@B16]; Shultz et al., [@B50]). Other than NSG mouse models in many cases lacked reliable engraftment of malignant cells. A reliable engraftment of malignant cells, best mimicking engraftment sites of human malignancies is essential for functional analysis of human cellular therapies in preclinical animal models.

In this study we focused on the principal biological characteristics and engraftment sites of human acute myeloid leukemia (AML) and RMS cells injected via the tail vein in sublethally irradiated NSG mice. In addition, IL-15-activated day 10 CIK cells were inoculated for functional analyses regarding anti-tumor, anti-leukemic and GvHD potential in NSG mice, which had received grafts of human AML and RMS cells.

Materials and Methods
=====================

AML and soft tissue sarcoma cells
---------------------------------

M4 subtype AML cell line, THP-1 was obtained and cultured as previously described (Rettinger et al., [@B41]). M2 subtype AML cell line, SH-2 was purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) and was maintained in IMDM medium supplemented with 20% fetal calf serum (FCS), [l]{.smallcaps}-glutamine, and antibiotics (penicillin 100 U/mL, streptomycin 100 μg/mL) according to the manufacturer's instructions. Alveolar RMS RH30, RH41, and embryonal RMS TE671 cell lines were obtained and cultured as described (Kuci et al., [@B27]). After written informed consent, primary Ewing's sarcoma cells were harvested from a resected thoracic tumor of a Ewing's sarcoma patient. The Ewing's sarcoma patient was diagnosed with the first relapse after allo-SCT. Ewing sarcoma samples were cryopreserved and subsequently thawed to be used in the experiments.

Generation of CIK cells
-----------------------

The Ethical Review Board of the Medical Faculty of the University Hospital Frankfurt/Main, Germany approved the study protocol to take blood from healthy volunteers after written informed consent for the purpose of generating cellular therapies against leukemia and soft tissue sarcomas (Geschäfts-Nr. 298/07). CIK cells were generated from peripheral blood mononuclear cells (PBMC) after standard Ficoll separation as previously described (Rettinger et al., [@B41]). In brief, cells were resuspended at a density of 3 × 10^6^ cells/mL in RPMI 1640, supplemented with 10% FCS, [l]{.smallcaps}-glutamine and antibiotics and primed by adding 1000 U/mL IFN-γ on day 0 and 100 ng/mL anti-CD3 antibody (MACS GMP CD3 pure, Miltenyi Biotech, Bergisch Gladbach, Germany) and 500 U/mL IL-2 within the following 24 h of culture. At day 4 of culture, cell density was adjusted to 1 × 10^6^ cells/mL. About 500 U/mL IL-2 or 50 ng/mL IL-15 and culture medium were added every 3 days, respectively. CIK cells were expanded over 10 days. On day 10 of culture CIK cells were harvested and used for analysis.

*In vitro* cytotoxicity analysis by Europium release assays
-----------------------------------------------------------

Europium release assay was used for *in vitro* cytotoxicity analysis as previously described (Rettinger et al., [@B41]). In brief, target cells were labeled with BATDA (Perkin Elmer, Boston, USA) washed and co-cultured with CIK cells in duplicates or triplicates at an effector to target cell ratio (E:T ratio) of 20:1 in U-bottom-96-well culture plates (NUNC, Roskilde, Denmark). Supernatant was collected from each well and co-incubated with europium solution (Europium, Perkin Elmer, Turku, Finland) on flat-bottom-96-well plates (NUNC, Roskilde, Denmark). Fluorescence data were recorded using a time resolved fluorometer (1420-018 Victor, Perkin Elmer, Waltham, MA, USA). The percentage of specific cytolysis was calculated for each well as described previously (Rettinger et al., [@B41]), and means with SD were calculated from each duplicate or triplicate.

Establishment of mouse models for human AML and RMS
---------------------------------------------------

NSG mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and were maintained in the animal facilities of the University of Frankfurt/Main, Germany under specific pathogen-free conditions. The described research was approved by the Animal Care Committee of Frankfurt am Main University and the Regierungspräsidium Darmstadt, Germany (Gen. Nr. F. 133/08).

For the establishment of human leukemia and RMS models in mice, 6- to 8-week old NSG mice were sublethally irradiated with 200 cGy 24 h prior to intravenous (i.v.) injection of AML or RMS cells (Biobeam 2000, Eckert and Ziegler, Bebig, Germany). Subsequently, mice received tail vein injections of either 1 × 10^4^ or 1 × 10^3^ THP-1 cells. In parallel, mice were transplanted with 5 × 10^6^, 2.5 × 10^6^, 1 × 10^6^, or 0.5 × 10^6^ SH-2 cells. For RMS engraftment, mice were inoculated with 1 × 10^6^ RH41 cells or 1 × 10^5^ RH30 cells, respectively.

Animals were euthanized on days 5, 15, 25, 30, 32, and 45 after transplantation of malignant cells, or monitored for survival. Mice showing visible signs of poor health or physical abnormalities were sacrificed. Mice were sacrificed by carbon dioxide asphyxiation followed by cervical dislocation.

CIK cell treatment of AML or RMS mice
-------------------------------------

In the first series of experiments, mice were inoculated i.v. with the minimal cell dose of 1 × 10^4^ THP-1 cells and 1 × 10^6^ RH41 cells sufficient to induce cancer. Randomly selected mice were injected with 1 × 10^6^ IL-15-activated day 10 CIK cells 1 day after transplantation of malignant cells.

In the second series of experiments CIK cell dose was increased to 2.5 × 10^6^ cells and CIK cells were inoculated 24 h after injection of 1 × 10^4^ THP-1 cells into randomly selected mice. THP-1 and RH41 injected mice were sacrificed 25 and 45 days after transplantation of malignant cells and organs were analyzed for engraftment of malignant cells.

Harvest of human cells from organs of NSG mice
----------------------------------------------

Cell suspensions of liver, spleen, lung, brain, PB, and BM were prepared. Briefly, BM cells were collected from each tibia and femur by flushing bones with culture medium. Mouse erythrocytes within BM and PB samples were lysed with lysing buffer (Mouse Erythrocyte Lysing Kit, R&D Systems, Wiesbaden, Germany) and washed once with washing buffer (Mouse Erythrocyte Lysing Kit, R&D Systems, Wiesbaden, Germany) according to the manufacturer's instructions. Other cell suspensions were prepared from mouse organs digested by collagenase, filtered through a 100-μM cell strainer and washed with phosphate buffered saline (PBS). Aliquots of cell suspensions were analyzed by four-color flow cytometry analysis (FACS) and quantitative polymerase chain reaction (qPCR).

Quantification and characterization of human cells in the organs of NSG mice by FACS
------------------------------------------------------------------------------------

Leukemia burden in CIK cell treated and untreated mice were quantified by FACS. In addition, CIK cells were characterized by FACS. Cells were washed once in PBS resuspended in 100 μL PBS, and incubated with fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, phycoerythrin--cyanin (Cy) 5-, or allophycocyanin (APC)-conjugated-anti human monoclonal antibodies (mAbs) for 20 min at 4°C, washed twice in PBS and resuspended in 200 μL of PBS. The frequency of human CD45 (FITC, PerCP, APC, BD Biosciences, Heidelberg, Germany; PE, BD Pharmingen, Heidelberg, Germany), CD3 (PE, PerCP, BD Biosciences; APC, BD Pharmingen), CD4 (FITC, APC, BD Pharmingen), CD8 (FITC, PE, BD Biosciences; APC, BD Pharmingen), CD25 (PE, BD Pharmingen), CD56 (FITC, PE, BD Biosciences; APC, BD Pharmingen), TCRαβ (PE, Miltenyi Biotec, Bergisch Gladbach Germany), TCRγδ (FITC, BD Biosciences), and CD33 (PerCP, BD Biosciences) expressing cells was analyzed. Isotype-matched fluorochrome-conjugated IgGs were used as controls. After gating on viable cells, data on 5 × 10^5^ events were acquired by flow cytometer BD FACSCalibur (BD Biosciences) using Cell Quest software (BD Biosciences).

Quantification and discrimination of human cells in the organs of NSG mice by PCR
---------------------------------------------------------------------------------

DNA PCR was performed from cell suspensions as previously described (Kuci et al., [@B26]). In brief, genomic DNA was extracted using the QIAamp blood and tissue kit (Qiagen, Hilden, Germany). As a first step a quantitative real time PCR approach was used to assess the amount of human cells of each tissue sample by specific amplification of the human albumin gene (Pongers-Willemse et al., [@B38]). As a standard was used the serial dilution preparation of human DNA in mouse DNA. For each reaction 50 ng DNA were processed and the assay was able to detect one human cell beneath 1000 murine cells. As a second step within the human cell fraction proportion of CIK and tumor cells were discriminated by human specific STR-genotyping similar to chimerism analyses (Scharf et al., [@B45]). Informative loci for the discrimination of THP-1 and CIK cells were D7S820 and for the discrimination of RH41 and CIK cells D3S1358, D13S317, and D18S51, respectively. Leukemia or tumor burden of each mouse was obtained by adding leukemia or tumor signals per analyzed organ. Primers and probes were achieved from Eurofins (Eurofins MWG GmbH, Ebersberg, Germany) and genotyping was performed using the STR multiplex PCR system Powerplex16 (Promega GmbH, Mannheim, Germany).

Histology
---------

Histological analysis was performed by mfd diagnostics (mfd diagnostics GmbH, Wendelsheim, Germany). Tissue was fixed in 100% buffered formalin, paraffin embedded, sectioned, and stained with hematoxylin--eosin (HE). Microscopy analysis was performed by mfd diagnostics using Zeiss AXIO Imager A1/M1.

Statistical analysis
--------------------

Results were compared using the paired Student's two tailed *t*-test. A *p*-value \<0.05 was considered to be significant.

Results
=======

*In vitro* cytotoxicity of CIK cells
------------------------------------

Our previous studies demonstrated that IL-15-activated CIK cells in part were superior in killing of leukemia cells compared with IL-2-stimulated CIK cells (Rettinger et al., [@B41]). This study was performed, to confirm these findings against a variety of sarcoma cells. After 10 days of *in vitro* culture IL-15-stimulated CIK cells and conventional IL-2-stimulated CIK cells were added to target cells at an E:T ratio of 20:1 and tested in europium release assays. Target cells used were TE671, RH30, primary Ewing's sarcoma and RH41 cells. Interestingly, IL-15 activation resulted in significantly increased cytotoxicity against TE671 (*p* \< 0.0237, Figure [1](#F1){ref-type="fig"}A), RH30 (*p* \< 0.0123, Figure [1](#F1){ref-type="fig"}B), and primary Ewing's sarcoma cells (*p* \< 0.0154, Figure [1](#F1){ref-type="fig"}C) compared to IL-2-activated CIK cells. *In vitro* cytotoxicity of IL-15-stimulated CIK cells was not increased against RH41 cells (Figure [1](#F1){ref-type="fig"}D). Altogether, IL-15-stimulation was vastly different among the individual cell lines and was equivalent of IL-2-stimulation in RH41 cells *in vitro*.

![**Increased cytotoxic potential of IL-15-stimulated cytokine-induced killer cells against sarcoma cells**. Cytotoxicity of IL-15-stimulated and conventional IL-2-stimulated CIK cells after 10 days of culture against embryonal rhabdomyosarcoma (RMS) cell line TE671 **(A)**, alveolar RMS cell lines RH30 **(B)** and RH41 **(D)**, and primary Ewing's sarcoma cells **(C)** was analyzed by europium release assay *in vitro*. Mean values from three independent experiments are shown. IL-15-activated CIK cells exhibited a significantly increased cytotoxicity against TE671 (*p* \< 0.0237), RH30 (*p* \< 0.0123) and primary Ewing's sarcoma cells (*p* \< 0.0154) compared to IL-2-activated CIK cells. Cytotoxicity of IL-15-activated CIK cells was not increased against RH41 cells **(D)**.](fonc-02-00032-g001){#F1}

Establishment of human AML and RMS models in NSG mice
-----------------------------------------------------

We suggested that IL-15-activated CIK cells may have differential effects *in vivo* compared with our *in vitro* findings, and therefore may also be effective against RH41 and THP-1 cells *in vivo*, which both were equivalent killed by IL-2- and IL-15-activated CIK cells (Rettinger et al., [@B41]). Besides RH41 and THP-1 models, we established additional xenotransplant models of both tumor entities, AML and RMS, in immunodeficient NSG mice. Taking into consideration the excellent proliferative capacity of AML cells, we performed dose-finding experiments to determine the minimal AML dose required for a delayed, but reliable engraftment of human AML cells. The determined cell dosage differed markedly between cell lines, and was 1 × 10^4^ in case of fast-expanding THP-1 cells (manufacturer's instructions: doubling time, 35--50 h; Figure [2](#F2){ref-type="fig"}A) and 0.5 × 10^6^ in case of slowly expanding SH-2 cells (manufacturer's instructions: doubling time, 80 h; Figure [2](#F2){ref-type="fig"}B). However, despite injection of a minimum of THP-1 cells, mice showed physical abnormalities within 24--34 days after injection, whereas mice injected with a minimum of SH-2 cells developed symptoms within a period of 82--103 days post-transplant. Further analyses of organs of affected mice showed that most of the THP-1 engraftment took place in the BM, but was also decreasingly detectable in lung, spleen, liver, PB, and brain (Figure [2](#F2){ref-type="fig"}C). The earliest time point for PCR-based detection of THP-1 engraftment within analyzed organs (BM, PB, liver, spleen, lung, and brain) taken together was 15 days after transplantation. From then, cells expanded dramatically 665-fold (day +15, 0.20; day +32, 132.95) within a period of 17 days (Figure [2](#F2){ref-type="fig"}D).

![**Establishment of humanized acute myeloid leukemia mouse models**. Preclinical AML models were established in immunodeficient NSG mice. Results from three independent experiments are shown. Minimal cell doses required for AML engraftment were 1 × 10^4^ in case of THP-1 cells **(A)** and 0.5 × 10^6^ in case of SH-2 cells **(B)**. Mice injected with a minimum of THP-1 cells showed disease development within 24--34 days **(A)**. Mice injected with a minimum of SH-2 cells developed disease within 82--103 days **(B)**. PCR-based detection of human albumin showed that most of the THP-1 engraftment occurred in the bone marrow (BM), but was also detectable at decreasing amounts in lung, spleen, liver peripheral blood (PB), and brain **(C)**. THP-1 engraftment within bone marrow (BM), peripheral blood (PB), liver, spleen, lung, and brain taken together increased by 665-fold (day +15, 0.20; day +32, 132.95) within 17 days **(D)**.](fonc-02-00032-g002){#F2}

According to their proliferative capacity, 1 × 10^5^ of RH30 cells (manufacturer's instructions: doubling time, 35 h) and 1 × 10^6^ of RH41 cells (manufacturer's instructions: doubling time, 24--36 h) were found to be sufficient for tumorigenesis. RMS engraftment of RH30 and RH41 cells was monitored at days +15, +30 and \>+45 post-transplant. Engraftment of RH30 cells in BM, PB, liver, spleen, and lung taken together was detectable 15 days after transplantation (Figure [3](#F3){ref-type="fig"}A), and RH30 injected mice, which were observed for survival, became ill 48--69 days after injection. Most of the RMS engraftment took place within the reticuloendothelial system (RES) of the liver (Figures [3](#F3){ref-type="fig"}B,C), but was also detectable to a decreasing extent in lung, BM, spleen, and PB (Figure [3](#F3){ref-type="fig"}D). PCR results demonstrated that RH30 cells expanded 627-fold (day +15, 0.21; \>day +45, 131.71; Figure [3](#F3){ref-type="fig"}A). RH41 signals within analyzed compartments (BM, PB, liver, spleen, and lung) taken together were detected at day +15 (Figure [3](#F3){ref-type="fig"}E), and RH41 mice, which were observed for survival, showed signs of discomfort 45--51 days after transplantation. Expansion rate of RH41 cells, which were injected at higher cell doses compared with RH30 cells was 18020-fold (day +15, 0.01; \>day +45, 180.20) within 30 days after RMS engraftment (Figure [3](#F3){ref-type="fig"}E). Most of the RH41 engraftment took place in liver and lung, but was also detectable to a decreasing extent in BM, PB, and spleen (Figures [3](#F3){ref-type="fig"}F,G).

![**Establishment of humanized rhabdomyosarcoma mouse models**. Results from three independent experiments demonstrated that intravenous injection of 1 × 10^5^ RH30 cells was sufficient for tumorigenesis. PCR-based detection of human albumin in bone marrow (BM), peripheral blood (PB), liver, spleen, and lung taken together showed that RH30 cells engrafted by day +15 and expanded 627-fold within 30 days **(A)**. Most of the RH30 engraftment occurred within the reticuloendothelial system (RES) of the liver as shown by HE-staining of one representative histological analysis **(B)**, but was also detectable to a decreasing extent in lung, bone marrow (BM), spleen, and peripheral blood (PB) **(C,D)**. In parallel, injection of 1 × 10^6^ RH41 cells was sufficient for engraftment of tumor cells. RH41 signals within analyzed compartments (BM, PB, liver, spleen, and lung) were detectable at day +15 and increased by 18020-fold within 30 days **(E)**. Most of RH41 engraftment occurred in liver and lung like shown by one representative example **(F)**, but was also detectable in bone marrow, blood, and spleen **(G)**.](fonc-02-00032-g003){#F3}

*In vivo* cytotoxicity of IL-15-stimulated CIK cells against RMS
----------------------------------------------------------------

Having established the xenotransplant tumor models, we assessed the cytotoxicity of IL-15-activated CIK cells after 10 days of *ex vivo* culture against RH41 cells *in vivo*. With regard to clinical translatability, RH41 cells were used best mimicking resistant tumor cells. NSG mice were sublethally irradiated and transplanted with 1 × 10^6^ RH41 cells. About 1 × 10^6^ CIK cells were injected in one part of RH41-transplanted mice 24 h after tumor cell injection. CIK cell treated mice and untreated controls were analyzed for RMS engraftment 45 days after injection of RH41 cells. Gross examination of organs was equivalent in CIK cell treated and untreated mice. PCR-based results confirmed that small numbers of injected CIK cells were able to migrate to sites where tumor was found (Figure [4](#F4){ref-type="fig"}A). Furthermore, these CIK cells were capable of significantly reducing RH41 burden by comparing compartments of CIK cell treated mice (Figure [4](#F4){ref-type="fig"}A) with untreated controls (Figure [4](#F4){ref-type="fig"}B) where RH41 cells were detectable. Results of analyzed compartments taken together confirmed that CIK cell treatment (*n* = 3) resulted in a significantly reduced tumor burden compared with the untreated controls (*n* = 5; control group, 180 ± 104; treatment group, 67 ± 6, *p* \< 0.001; Figure [4](#F4){ref-type="fig"}C).

![***In vivo* cytotoxicity of IL-15-stimulated cytokine-induced killer cells against rhabdomyosarcoma**. CIK cell treated (*n* = 3) and untreated controls (*n* = 5) among RH41-transplanted mice were analyzed 45 days after transplantation of malignant cells. Chimerism analyses of one representative example within the treatment group showed that CIK cells were detectable in the liver spleen and lung **(A)**. RH41 engraftment was most pronounced in liver and lung, but was also seen to a lesser extent in the bone marrow (BM) and spleen like shown by one representative untreated control **(B)**. PCR results from all analyzed organs of the treatment and control group (untreated mice, *n* = 5; CIK cell treated mice, *n* = 3) taken together showed, that CIK cells were able to significantly reduce tumor growth when compared to untreated mice \[*p* \< 0.001, **(C)**\].](fonc-02-00032-g004){#F4}

*In vivo* cytotoxicity of IL-15-stimulated CIK cells against AML
----------------------------------------------------------------

Cytotoxicity of IL-15-stimulated day 10 CIK cells was determined in THP-1-injected mice 25 days after transplantation. Previously analyzed, fast-expanding THP-1 cells (Rettinger et al., [@B41]) were used in this study best representing AML engraftment in patients. Groups of mice inoculated with 1 × 10^4^ THP-1 cells were injected with different doses of CIK cells. To this end, 1 × 10^6^ or 2.5 × 10^6^ CIK cells were transplanted via the tail vein in THP-1-injected mice. Despite aggressive expansion of THP-1 cells, PCR-based results demonstrated that CIK cells were capable of reducing THP-1 burden in all analyzed compartments (BM, PB, liver, spleen, lung, and brain) taken together. Furthermore, our results demonstrated that cytotoxicity of CIK cells was dose-dependent (untreated control group, 161 ± 56; treatment groups, 1 × 10^6^ CIK cells, 74 ± 56; 2.5 × 10^6^ CIK cells, 43 ± 35, *p* \< 0.0001, Figure [5](#F5){ref-type="fig"}A). In this series of experiments, chimerism analysis was used to determine THP-1 and CIK cell signals in BM, liver, spleen, lung, brain, and PB of mice (Figure [5](#F5){ref-type="fig"}B). Comparable results were obtained by FACS analysis of BM samples of CIK cell treated mice and untreated controls (Figure [5](#F5){ref-type="fig"}C). Here, THP-1 cells were quantified by staining with human anti-CD45 and anti-CD33 antibodies. Engraftment of THP-1 cells (CD45^+^CD33^+^) and CIK cells (CD45^+^CD33^−^) was negatively correlated and THP-1 engraftment was even inhibited in two out of seven mice injected with 2.5 × 10^6^ CIK cells (Figure [5](#F5){ref-type="fig"}C). THP-1 engraftment was markedly reduced but not inhibited after injection of 1 × 10^6^ CIK cells. This might be due to the fact that compared to THP-1 expansion, CIK cell expansion was delayed and CIK cells (CD45^+^) were not detectable within 30 days post-transplant like shown by anti-CD45 staining within organs of representative examples after injection of 1 × 10^6^ CIK cells only (Figure [5](#F5){ref-type="fig"}D). FACS analysis of organs of THP-1-injected mice treated with 2.5 × 10^6^ CIK cells (CD3^+^) confirmed that CIK cells infiltrated leukemia sites, resulting in a reduction or even elimination of CD33^+^ expressing THP-1 cells (Figure [5](#F5){ref-type="fig"}E). In this analysis CIK cells were detected by staining them with a human anti-CD3 antibody whereas THP-1 cells were quantified by staining with a human anti-CD33 antibody.

![**Anti-leukemic activity of IL-15-stimulated cytokine-induced killer cells**. Mice were inoculated i.v. with the minimal leukemic dose of 1 × 10^4^ THP-1 cells. About 1 × 10^6^ and 2.5 × 10^6^ CIK cells were transplanted via the tail vein into one part of mice injected with THP-1 cells. Bone marrow (BM), peripheral blood (PB), liver, spleen, lung, and brain were analyzed for THP-1 and CIK cell engraftment by PCR 25 days after transplantation of malignant cells. Results of analyzed compartments taken together showed that CIK cell treatment resulted in a markedly decreased THP-1 engraftment compared with the untreated controls **(A)**. Reduction of leukemia burden was dose-dependent. Chimerism analysis was used to distinguish between AML and CIK cells. Chimerism results like shown here by one representative example \[mouse no. 7, 1 × 10^4^ THP-1 cells and 2.5 × 10^6^ CIK cells, **(B)**\] demonstrated that CIK cells were detectable in analyzed organs. Except the brain, THP-1 signals were not detectable in CIK cell infiltrated organs. Bone marrow results obtained by flow cytometry, confirmed that CIK cells (CD45^+^CD33^−^) were capable of reducing AML (CD45^+^CD33^+^) engraftment in a dose-dependent manner **(C)**. Representative examples of mice injected with 1 × 10^6^ CIK cells (CD45^+^) only, demonstrated that CIK cells expanded as early as 30 days post-transplant **(D)**. Therefore, expansion of 1 × 10^6^ injected CIK cells was delayed compared with THP-1 engraftment. Flow cytometry analysis from seven independent experiments within the treatment group which were performed 25 days after THP-1 injection confirmed that CIK cells (CD3^+^) injected at higher doses (2.5 × 10^6^ CIK cells) were capable of reducing or even eliminating AML (CD33^+^) engraftment **(E)**.](fonc-02-00032-g005){#F5}

CIK cell phenotype and potential to induce GvHD
-----------------------------------------------

Flow cytometric analysis revealed that CIK cells at the time of injection displayed a CD3^+^CD56^−^ rather than CD3^+^CD56^+^ or CD3^−^CD56^+^ phenotype (Figure [6](#F6){ref-type="fig"}A). These T cells expressed CD8 and CD25 rather than CD4 molecules (Figure [6](#F6){ref-type="fig"}A). BM analyses of cancer-infiltrating CIK cells *in vivo* exclusively demonstrated a CD3^+^CD56^−^ T cell phenotype (Figure [6](#F6){ref-type="fig"}B). In addition, most of these T cells expressed CD4 rather than CD8 antigens (Figure [6](#F6){ref-type="fig"}B).

![**Phenotype and alloreactive potential of cytokine-induced killer cells**. Before injection, CIK cells were CD3^+^CD56^−^ or CD3^+^CD56^+^ rather than CD3^+^CD56^+^ like shown by FACS analyses of three independent examples **(A)**. Most of these T cells expressed CD8 and CD25 rather than CD4 antigens **(A)**. Cytometric analysis of injected CIK cells from seven independent bone marrow samples within the treatment group demonstrated predominantly a CD3^+^CD56^−^ T cell phenotype **(B)**. Most of these T cells were CD4^+^ rather than CD8^+^ **(B)**. Histological analysis from one representative CIK cell treated mouse with the best CIK cell engraftment (mouse no. 7, Figures [5](#F5){ref-type="fig"}B,E, 1 × 10^4^ THP-1 cells + 2.5 × 10^6^ CIK cells) showed no xenogenic GvHD in classical GvHD targeted tissues like gut and liver as well as in spleen, the preferred homing sites of CIK cells **(C)**.](fonc-02-00032-g006){#F6}

Graft-versus-host-disease targeted tissues like the gastrointestinal tract, liver, and spleen were analyzed in terms of xenogenic GvHD mediated by CIK cells. Histological analyses of gut, liver, and spleen of one representative mouse, with the highest degree of CIK cell expansion (mouse no. 7, Figures [5](#F5){ref-type="fig"}B,E) demonstrated no or mild xenogenic GvHD potential of IL-15-stimulated CIK cells (Figure [6](#F6){ref-type="fig"}C).

Discussion
==========

The aim of this study was to evaluate the efficacy of *ex vivo* expanded, IL-15-activated day 10 CIK cells against AML and sarcoma cells *in vivo* in an optimized preclinical mouse model with the goal of clinical translatability. We therefore established a disease model for AML and sarcoma cells in NSG mice injected via the tail vein with a minimal leukemic or tumorigenic dose. The feasibility and efficacy of infused CIK cells in AML and RMS bearing mice was then analyzed in terms of regression of malignant cells or alloreactivity of CIK cells.

Transplantation of human AML cells into different strains of immunodeficient mice has led to preclinical models used to investigate AML and sarcoma biology, and efficacy of immunotherapy (Bonnet and Dick, [@B6]; Hudson et al., [@B14]; Vormoor et al., [@B59]; Ito et al., [@B17]; Feuring-Buske et al., [@B9]; Meyerrose et al., [@B30]; Ishikawa et al., [@B16]; Kawano et al., [@B18]; Shultz et al., [@B50], [@B49]; Siegler et al., [@B51]). NSG mice have been investigated as models to generate human hematopoiesis in a murine host (Ito et al., [@B17]; Shultz et al., [@B50]). The IL-2Rγc-chain deficiency in NSG mice, also lacking functional B cells and T cells, impairs signaling through multiple cytokine receptors, which block NK cell development resulting in additional defects in innate immunity (Shultz et al., [@B50], [@B49]). Agliano et al. ([@B1]) observed a fast development of leukemia-related symptoms and a high percentage of leukemia cells in blood, BM, and spleen of intraperitoneally (i.p.) injected non-irradiated NSG mice. Total body irradiation in SCID mutant mice was reported to increase radiosensitivity, associated with some unpredictable mouse mortality (Shultz et al., [@B49]). In addition, recent reports showed a significant engraftment of human cells and a prolonged life span in non-irradiated NSG mice (Nakamura et al., [@B31]; Watanabe et al., [@B62]). Despite these observations, to best mimic conditioning prior to transplantation in humans, we decided to irradiate the animals before injection of human cells. Our results showed that tail vein injection of human AML and RMS cells resulted in a 100% engraftment of transplanted cells. We found that doses of 1 × 10^4^--1 × 10^6^ cells per mouse were sufficient to obtain with certainty leukemia or sarcoma engraftment within 3--8 weeks. We suggested that the log difference in cell requirement may depend on the proliferative capacity and migration characteristics of injected cells. As one reason, cell requirement was less in fast-expanding AML subtype M4 cells, and more in slowly expanding AML subtype M2 or RMS cells. We observed most of the leukemia engraftment in the BM, and most of the RMS engraftment in liver and lung. The RES of liver and lung usually represents with plenty of microvasculature, and velocity of blood flow inside is slow. Hence, it appears likely that infused RMS cells, which are larger than AML cells, were retained at these sites. In contrast to our finding, that 0.5 × 10^6^ i.v. injected SH-2 cells were sufficient for leukemic engraftment in NSG mice, other groups reported that 1 × 10^7^ subcutaneously (s.c.) or i.v. injected SH-2 cells were needed for engraftment in 5/8 BALB/c nude mice and 4/10 SCID mice 8 weeks after injection (Qiu et al., [@B40]). We suggest that a preclinical model with reliable engraftment rates is essential for analysis of cellular therapy.

Adoptive cellular immunotherapy is an important treatment to eliminate residual leukemia or tumor cells after allo-SCT. Over the past 20 years the development of CIK cell immunotherapy for the treatment of hematological and solid malignancies has received considerable attention. CIK cells are capable of a broad MHC-unrestricted anti-leukemic and anti-tumor activity as documented both *in vitro* and *in vivo* in murine models (Schmidtwolf et al., [@B48], [@B47]; Lu and Negrin, [@B29]; Hoyle et al., [@B13]; Sweeney et al., [@B53]; Alvarnas et al., [@B2]; Baker et al., [@B4]; Verneris et al., [@B57]; Edinger et al., [@B8]). Limited data are available on the efficacy of CIK cells against solid tumors (Scheffold et al., [@B46]; Wang et al., [@B61]; Helms et al., [@B12]; Sangiolo, [@B43]). In previous work we modified CIK cell generation by using IL-15 for CIK cell activation (Rettinger et al., [@B41]). IL-15 activation significantly enhanced CIK cell-mediated cytotoxicity against leukemia cells *in vitro*, whereas the alloreactive potential of IL-15-stimulated CIK cells remained low. Furthermore, we could show that IL-15 activation can minimize the culture period prior to adoptive transfer without affecting the *in vitro* efficacy of CIK cells. Hence, IL-15-stimulation may change the outcome of CIK cell generation from terminally differentiated and potentially exhausted day 21 CIK cells to day 10 CIK cells with a more naïve phenotype and potent proliferative capacity.

In our experiments, mice received grafts of human AML and RMS cells. In order to demonstrate that IL-15-activated CIK cells have differential effects *in vivo*, rather than *in vitro*, and to best mimic clinical situations of high-risk patients, RH41 cells resistant to FAS- and TRAIL-induced apoptosis (Petak et al., [@B35], [@B36]) and fast-expanding THP-1 cells, which were previously tested (Rettinger et al., [@B41]) were used as targets for *in vivo* analysis. TRAIL is important for CIK cell-mediated induction of apoptosis (Kuci et al., [@B27]). Therefore, TRAIL-resistance of RH41 cells may have influenced *in vitro* cytotoxicity of IL-15-activated CIK cells in this study.

Experimental mice were then assigned randomly to different treatment groups, and were infused with equal amounts of CIK cells in the RMS setting, and 100--250 times increased amounts of CIK cells compared with injected malignant cells in the leukemia setting. To avoid non-engraftment of leukemia and tumor cells by co-transplantation of CIK cells, CIK cells were injected at least 24 h after administration of malignant cells. We observed that i.v. injection of 2.5 × 10^6^ or 1 × 10^6^ CIK cells resulted in a strong inhibition of AML and sarcoma growth. Hereby CIK cells were capable of reducing AML engraftment in a dose-dependent manner after being injected within 24 h after administration of malignant cells. This time point might represent MRD status, and might therefore be optimal for MRD-directed preemptive immunotherapy. An excess of leukemia/tumor cells will likely not be overcome by immunological measures. Furthermore, our study results demonstrated, that CIK cells widely distributed to many organs through the blood stream. It was previously reported that CIK cells migrated to tumor sites within 7 h after injection, and remained detectable at these sites for an additional 9 days (Verneris et al., [@B58]; Edinger et al., [@B8]; Skitzki et al., [@B52]; Kornacker et al., [@B24]). Our results revealed the presence of considerable numbers of CIK cells in different compartments up to 51 days post-transplant. But, CIK cell movement via the blood circulation and CIK cell expansion at tumor sites depended on the number of CIK cells infused. Some reports showed that CIK cells first entered into the lung, after inoculation of nude mice (Hazelrigg et al., [@B11]; Kim et al., [@B19]), peaked there within 2--6 h after injection, then declined, and re-distributed to organs such as liver, spleen, and kidney within 24 h. Another report demonstrated that CIK cells infused via the tail vein homed directly to the RES (Li et al., [@B28]). In contrast, in our study aggregation and expansion of infused CIK cells mostly occurred in BM and spleen at the time of analysis.

Cytokine-induced killer cell populations undergo a maturation process during *ex vivo* expansion. During this process we could show in previous studies that CIK cell subpopulations arise with a maximum of anti-tumor activity and proliferative capacity within day 7--14 of culture (Kuci et al., [@B27]; Rettinger et al., [@B41]). Terminally differentiated effector CD3^+^CD56^+^ T cell subpopulations are known to possess potent cytotoxicity, but have low proliferative capacity (Wajchman et al., [@B60]; Powell et al., [@B39]). On the other hand, CD3^+^CD56^−^ cells, which represent early effector T cells, exhibit reduced cytotoxicity but a higher capacity for proliferation, home to lymphoid tissues, and persist *in vivo* (Gattinoni et al., [@B10]). Therefore the entire expanded CIK cell population may represent an ideal cell population for adoptive immunotherapy. The CD3^+^CD56^+^ subset could deliver potent cytotoxicity for the immediate destruction of malignant cells while the less potent CD3^+^CD56^−^ cell subset could proliferate and persist *in vivo* for a longer duration and therefore provide a continuous source of cells with long term cytotoxic activity. In addition, the small CD3^−^CD56^+^ NK cell subset has been shown to efficiently lyse MHC class I-deficient tumor targets that escape T cell recognition. The spleen is known to be the best organ to detect T cells, whereas NK cells are best detectable in BM (Varga et al., [@B56]). At the time of inoculation most of CIK cells showed CD3^+^CD56^−^ followed by CD3^+^CD56^+^ and CD3^+^CD56^−^ phenotype. Most of CD3^+^CD56^−^ CIK cells expressed CD8 and CD25 rather than CD4 molecules. After injection we detected CD3^+^CD56^−^ but no CD3^+^CD56^+^ or CD3^−^CD56^+^ cells at the time of analysis. In addition we demonstrated that persisting CD3^+^CD56^−^ cells were CD4^+^ rather than CD8^+^, suggesting that the phenotype of CIK cells at the time of adoptive transfer reverted without cytokine stimulation *in vivo* and resulted in an expansion of CD3^+^CD4^+^ CIK cells *in vivo*.

It was shown that adoptive transfer of allogeneic CIK cells in a murine model caused minimal GvHD-like symptoms as CIK cells infiltrated GvHD targeted tissues to a lesser degree and more transiently than conventional T cells (Baker et al., [@B4]; Verneris et al., [@B57]; Beilhack et al., [@B5]; Nishimura et al., [@B32]). Irradiated Balb/c mice tolerated up to 20 × 10^6^ day 14 CIK cells which caused minimal GvHD whereas as few as 2.5 × 10^6^ splenocytes, as a T cell equivalent in mice, induced acute lethal GvHD. As one reason, CIK cells showed a slower division rate, higher susceptibility to apoptosis, increased IFNγ release, and reduced expression of homing molecules (Duffner et al., [@B7]; Welniak et al., [@B63]; Nishimura et al., [@B32]). IFNγ has a protective effect against GvHD at early time points after transplantation. Homing molecules and chemokine receptors direct alloreactive cells toward GvHD targeted inflamed tissues. Irradiation induced tissue inflammation in our experimental setting. However, we observed only mild tissue damage in mice when infused CIK cells persisted and expanded at these sites. Affected mice showed minimal weight loss, and were somewhat hunched and scrubby.

In conclusion, human CIK cells traffic and survive in a murine recipient for prolonged periods of time with minimal xenogenic GvHD. CIK cells retain strong anti-leukemia and anti-tumor activity and homing capacity to leukemia and tumor sites. Therefore, CIK cells may be an effective alternative to prevent or treat leukemia or sarcoma relapse after allo-SCT. From our findings, we expect that the MRD state will be most susceptible to immunotherapy. Therefore diagnostics for MRD and preemptive immunotherapy using CIK cells to prevent relapse in patients with leukemia or sarcoma should be considered early after allo-SCT.
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